MA29880B1 - Inhibiteurs pde et combinaisons de ceux-ci pour traiter des troubles urinaires. - Google Patents

Inhibiteurs pde et combinaisons de ceux-ci pour traiter des troubles urinaires.

Info

Publication number
MA29880B1
MA29880B1 MA30864A MA30864A MA29880B1 MA 29880 B1 MA29880 B1 MA 29880B1 MA 30864 A MA30864 A MA 30864A MA 30864 A MA30864 A MA 30864A MA 29880 B1 MA29880 B1 MA 29880B1
Authority
MA
Morocco
Prior art keywords
treatment
pde
combinations
inhibitors
urological disorders
Prior art date
Application number
MA30864A
Other languages
English (en)
Inventor
Ernst Ulbrich
Peter Sandner
Hanna Tinel
Joachim Huetter
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37831473&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29880(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MA29880B1 publication Critical patent/MA29880B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)

Abstract

Inhibiteurs PDE et combinaisons de ceux-ci pour un traitement de troubles urologiques L'invention divulgue des compositions pharmacologiques contenant des inhibiteurs de PDE-5 et de PDE-4, seuls ou en combinaison, pour le traitement de troubles urologiques comprenant l'hyperplasie bénigne de la prostate (HBP), l'obstruction sous vésicale (BOO) et les symptômes du bas appareil urinaire (LUTS) et, en particulier, les symptômes d'irritation causés par l'obstruction sous-vésicale (BOO) induite par la HBP. L'invention divulgue aussi des procédés de criblage de tels inhibiteurs de PDE-5 et de PDE-4 à utiliser, seuls et en combinaison, dans la préparation de médicaments pour le traitement desdits troubles urologiques.
MA30864A 2005-09-29 2008-04-23 Inhibiteurs pde et combinaisons de ceux-ci pour traiter des troubles urinaires. MA29880B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05021261 2005-09-29
EP06007776 2006-04-13

Publications (1)

Publication Number Publication Date
MA29880B1 true MA29880B1 (fr) 2008-10-03

Family

ID=37831473

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30864A MA29880B1 (fr) 2005-09-29 2008-04-23 Inhibiteurs pde et combinaisons de ceux-ci pour traiter des troubles urinaires.

Country Status (23)

Country Link
US (1) US20090186896A1 (fr)
EP (1) EP1931797A2 (fr)
JP (1) JP2009509984A (fr)
KR (1) KR20080056250A (fr)
AR (1) AR057867A1 (fr)
AU (1) AU2006299232A1 (fr)
BR (1) BRPI0616633A2 (fr)
CA (1) CA2623657A1 (fr)
CR (1) CR9840A (fr)
DO (1) DOP2006000207A (fr)
EC (1) ECSP088311A (fr)
GT (1) GT200600442A (fr)
IL (1) IL190201A0 (fr)
MA (1) MA29880B1 (fr)
NO (1) NO20081973L (fr)
PE (1) PE20070587A1 (fr)
RU (1) RU2435588C2 (fr)
SG (1) SG166106A1 (fr)
SV (1) SV2009002851A (fr)
TN (1) TNSN08147A1 (fr)
TW (1) TW200804603A (fr)
UY (1) UY29816A1 (fr)
WO (1) WO2007039075A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007113243A2 (fr) * 2006-03-31 2007-10-11 Investigación Y Clínica Andrológicas S.L. Utilisation des inhibiteurs de la pde 5 pour le traitement de la vessie hyperactive
RU2009145935A (ru) * 2007-05-12 2011-06-20 Байер Шеринг Фарма Акциенгезельшафт (DE) Стимуляторы ргц, активаторы ргц и комбинации для лечения урологических нарушений
WO2008157205A2 (fr) * 2007-06-15 2008-12-24 Duke University Procédés et compositions pour le traitement des infections de l'appareil urinaire en utilisant des agents qui imitent ou augmentent l'amp cyclique
WO2009045019A2 (fr) * 2007-10-02 2009-04-09 Dong-A Pharm.Co., Ltd. Composition et méthode pour le traitement ou la prévention de l'hyperplasie bénigne de la prostate et des symptômes du tractus urinaire inférieur
US20090136473A1 (en) * 2007-11-21 2009-05-28 Decode Genetics Ehf Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders
EP2156847A1 (fr) * 2008-08-19 2010-02-24 Sanofi-Aventis Nouvelle combinaison d'ingrédients actifs contenant un alpha1-antagoniste et un inhibiteur de PDE 4
EP2266567A1 (fr) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Composition pharmaceutique comprenant de Cetrorelix e d'inhibiteurs de PDE V pour le traitement des étas dépendants de l'hormone sexuel
EP2266568A1 (fr) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Composition pharmaceutique comprenant d'antagonistes de LHRH et d'inhibiteurs de PDE V pour le traitement des états dépendants de l'hormone sexuel
JP2011184433A (ja) * 2010-02-09 2011-09-22 Daiichi Sankyo Healthcare Co Ltd バルデナフィル含有内服液剤組成物
JO3264B1 (ar) 2013-03-13 2018-09-16 Lilly Co Eli مركبات ازيتيدينيل أوكسي فينيل بيروليدين
KR102239291B1 (ko) * 2013-06-28 2021-04-14 한미약품 주식회사 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
EP3082428A4 (fr) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Formulations en poudre d'inhibiteur pde5 et procédés y associés
JP2016540017A (ja) * 2013-12-11 2016-12-22 アイアンウッド ファーマシューティカルズ インコーポレイテッド ｓＧＣ刺激物質
CA3128705A1 (fr) 2014-08-12 2016-02-18 Mezzion Pharma Co., Ltd. Procedes d'amelioration de la performance du myocarde chez des patients operes d'un fontan, au moyen de compositions d'udenafil
WO2016033776A1 (fr) 2014-09-04 2016-03-10 Eli Lilly And Company (2s)-3-[(3s,4s)-3-[(1r)-1-hydroxyéthyl]-4-(4-méthoxy-3-{[1-(5-méthylpyridin-2-yl)azétidin-3-yl]oxy}phényl)-3-méthylpyrrolidin-1-yl]-3-oxopropane-1,2-diol cristallin
TW201625591A (zh) 2014-09-12 2016-07-16 美國禮來大藥廠 吖丁啶基氧苯基吡咯啶化合物
PL3562485T3 (pl) 2018-03-23 2020-11-16 Laboratoires Major Niehormonalne kompozycje i sposoby antykoncepcji u mężczyzn z wykorzystaniem (r)-silodozyny
CN113490739A (zh) * 2019-01-23 2021-10-08 通路治疗公司 通过磷酸二酯酶4(pde4)抑制治疗癫痫的方法

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2705715A (en) * 1952-10-29 1955-04-05 American Cyanamid Co Purine compounds and methods of preparing the same
CH367510A (de) * 1957-11-27 1963-02-28 Ciba Geigy Verfahren zur Herstellung neuer Sulfonamide
GB1051734A (fr) * 1963-01-16
GB1042471A (en) * 1963-01-16 1966-09-14 Ilford Ltd Penta-azaindenes, their production and use in photographic emulsions
US3169129A (en) * 1963-05-10 1965-02-09 American Cyanamid Co 2-ortho-hydroxy-phenyl-4-(3h)-quinazolinones
USRE26565E (en) * 1966-03-02 1969-04-29 Table iii
GB1493685A (en) * 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
BE791025A (fr) * 1971-11-19 1973-05-07 Allen & Hanburys Ltd Composes heterocycliques
GB1457873A (en) * 1973-01-04 1976-12-08 Allen & Hanburys Ltd Imidazotriazines
US4052390A (en) * 1973-06-12 1977-10-04 May & Baker Limited Azapurinones
US4060615A (en) * 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
GB1561345A (en) * 1976-10-22 1980-02-20 May & Baker Ltd 8 - azapuring - 6 - ones
US4159330A (en) * 1976-11-02 1979-06-26 Carlo Erba S.P.A. 2-Disubstituted phenyl-3,4-dihydro-4-oxo-quinazoline derivatives and process for their preparation
DK109578A (da) * 1977-03-25 1978-09-26 Allen & Hanburys Ltd Fremgangsmaade til fremstilling af heterocycliske forbindelser
EP0054132B1 (fr) * 1980-12-12 1984-10-10 Dr. Karl Thomae GmbH Pyrimidones, leur préparation et médicaments les contenant
US4431440A (en) * 1981-02-20 1984-02-14 American Cyanamid Company Method to alter or control the development and/or the life cycle of various plant species
US4666908A (en) * 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
CA1303037C (fr) * 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Derives de purinone utilises comme bronchodilatateurs,vasodilatateurs et agents anti-allergiques
US5254571A (en) * 1988-04-21 1993-10-19 Smith Kline & French Laboratories Ltd. Chemical compounds
EP0347146B1 (fr) * 1988-06-16 1993-09-01 Smith Kline & French Laboratories Limited Dérivés de pyrimidine condensés, procédé et intermédiaires pour leur préparation et compositions pharmaceutiques les contenant
US5075310A (en) * 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
US4923874A (en) * 1988-07-21 1990-05-08 G. D. Searle & Co. Use of 8-azapurin-6-one derivatives for control of hypertension
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB8827988D0 (en) * 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
US5574020A (en) * 1989-09-28 1996-11-12 Eli Lilly And Company Tilmicosin formulation
CA2076983A1 (fr) * 1990-04-11 1991-10-12 Robert Wu-Wei Shen Revetement en lit fluidise permettant de masquer le gout de l'ibuprofene
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
US5316906A (en) * 1991-08-23 1994-05-31 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
GB9126260D0 (en) * 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5734053A (en) * 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9218322D0 (en) * 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
DE19540642A1 (de) * 1995-11-01 1997-05-07 Stief Christian Georg Priv Doz Verwendung von Inhibitoren der Phosphodiesterase bei der Behandlung von Prostataerkrankungen
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
DE59803108D1 (de) * 1997-11-12 2002-03-21 Bayer Ag 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren
US6221402B1 (en) * 1997-11-20 2001-04-24 Pfizer Inc. Rapidly releasing and taste-masking pharmaceutical dosage form
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
DE19827640A1 (de) * 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
IL132406A0 (en) * 1998-10-21 2001-03-19 Pfizer Prod Inc Treatment of bph with cgmp elevators
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
WO2001017479A2 (fr) * 1999-09-09 2001-03-15 Androsolutions, Inc. Methodes et compositions pour prevenir et traiter les troubles de la prostate
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
US6503908B1 (en) * 1999-10-11 2003-01-07 Pfizer Inc Pharmaceutically active compounds
CN1434825A (zh) * 1999-12-24 2003-08-06 拜尔公司 咪唑并[1,3,5]三嗪酮及其应用
EP1365806A2 (fr) * 2000-04-19 2003-12-03 Johns Hopkins University Utilzation d'activators de no pour le traitement et la prevention des troubles gastrointestinaux
WO2002036126A1 (fr) * 2000-10-30 2002-05-10 Lupin Limited Composition de cefuroxime axetil a liberation lente et a desintegration rapide
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
CN100372536C (zh) * 2001-02-15 2008-03-05 田边三菱制药株式会社 在口腔中迅速崩解的片剂
DE10118306A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
BR0209541A (pt) * 2001-05-09 2004-04-20 Bayer Healthcare Ag Uso das imidazotriazinonas 2-fenil-substituìdas
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
US7118765B2 (en) * 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
DE10325813B4 (de) * 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
ATE542546T1 (de) * 2003-11-20 2012-02-15 Astellas Pharma Inc Pde 4 inhibitoren zur behandlung der interstitiellen cystitis
RU2388466C2 (ru) * 2004-04-27 2010-05-10 Медисинова, Инк. Производные феноксиалкилкарбоновых кислот при лечении воспалительных заболеваний
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
WO2006104870A2 (fr) * 2005-03-25 2006-10-05 Schering Corporation Methodes de traitement d'hyperplasie prostatique benigne ou de symptomes des voies urinaires inferieures faisant appel a des inhibiteurs de pde 5
CA2612917A1 (fr) * 2005-06-23 2007-01-04 Schering Corporation Formulations orales a absorption rapide d'inhibiteurs de la pde5
RU2009145935A (ru) * 2007-05-12 2011-06-20 Байер Шеринг Фарма Акциенгезельшафт (DE) Стимуляторы ргц, активаторы ргц и комбинации для лечения урологических нарушений

Also Published As

Publication number Publication date
BRPI0616633A2 (pt) 2011-06-28
KR20080056250A (ko) 2008-06-20
AU2006299232A1 (en) 2007-04-12
WO2007039075A2 (fr) 2007-04-12
GT200600442A (es) 2007-05-15
JP2009509984A (ja) 2009-03-12
PE20070587A1 (es) 2007-08-17
CA2623657A1 (fr) 2007-04-12
DOP2006000207A (es) 2007-07-15
TW200804603A (en) 2008-01-16
AR057867A1 (es) 2007-12-26
RU2435588C2 (ru) 2011-12-10
UY29816A1 (es) 2007-04-30
RU2008116547A (ru) 2009-11-10
TNSN08147A1 (en) 2009-07-14
ECSP088311A (es) 2008-06-30
SG166106A1 (en) 2010-11-29
SV2009002851A (es) 2009-01-14
EP1931797A2 (fr) 2008-06-18
CR9840A (es) 2008-10-31
NO20081973L (no) 2008-06-20
US20090186896A1 (en) 2009-07-23
WO2007039075A3 (fr) 2007-06-21
IL190201A0 (en) 2008-11-03

Similar Documents

Publication Publication Date Title
MA29880B1 (fr) Inhibiteurs pde et combinaisons de ceux-ci pour traiter des troubles urinaires.
FR16C0021I2 (fr) Azetidines en tant qu'inhibiteurs de mek et leur utilisation pour le traitement des maladies proliferatives
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA29713B1 (fr) Derives de tetrahydroindolone et de tetrahydroindazolone
HUP0100586A2 (hu) Alsó húgyvezetéki tünetek kezelésére alkalmas gyógyászati készítmények
TW200609231A (en) Mglur1 antagonists as therapeutic agents
WO2006044497A3 (fr) Composes de spiropiperidine utilises comme inhibiteurs de beta-secretase en vue du traitement de la maladie d'alzheimer
MA30900B1 (fr) Anticorps d'agonistes anti-notch3 et leur utilisation dans le traitement de maladies liées à notch3
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
EP2295433A3 (fr) Inhibiteurs de JNK
EP1562897A4 (fr) Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer
MA31283B1 (fr) Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse
WO2007038209A3 (fr) Antagonistes du mglur1 tetracycliques fusionnes utilises en tant qu'agents therapeutiques
WO2004062625A3 (fr) Inhibiteurs de beta-secretase macrocyclique pour traiter la maladie d'alzheimer
MA28673B1 (fr) Derives de pyrazole, compositions contenant lesdits composes et methodes d'utilisation
MA31867B1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
WO2005018545A3 (fr) Inhibiteurs macrocycliques de la beta-secretase destines au traitement de la maladie d'alzheimer
MA30041B1 (fr) Immunoglobulines
MX2008002366A (es) Antagonistas triciclicos fusionados de mglur1 como agentes terapeuticos.
TN2009000332A1 (fr) Heterocycles bicycliques, medicament comprenant ces composes,leur utilisation et leur procede de preparation
TW200740826A (en) Fused tricyclic mGluR1 antagonists as therapeutic agents
EA200700963A1 (ru) ТЕРАПЕВТИЧЕСКИЕ ПИРАЗОЛО[3,4-b]ПИРИДИНЫ И ИНДАЗОЛЫ
EP2073635A4 (fr) Inhibiteurs de spiropipéridine macrocyclique de bêta-secrétase pour le traitement de la maladie d'alzheimer
DE602004019500D1 (en) 4-substituirte-5-cyano-1h-pyrimidin-6-(th)iones als als gsk-3-hemmer